What evidence does the news provide that Hong Kong is experiencing a structural shift in attracting international IPOs?

The news states that Johnson Chui, HKEX's head of global issuer services, called the current pipeline 'the start of a structural change of the next phase of international companies listing in Hong Kong' and emphasized that the city's appeal has 'widened beyond companies with China exposure', citing 'very successful examples for companies that have no business at all in this part of the world' — indicating a fundamental broadening of the investor–issuer nexus beyond Greater China exposure.

Which foreign companies or sectors are explicitly named in the news as part of Hong Kong's 2026 IPO pipeline, and what types of listing structures are involved?

The news names Engine Biosciences (Singapore, biotech), NiKang Therapeutics (U.S., biotech), Teleport (Malaysia, logistics), Blockdaemon (U.S., blockchain infrastructure), Capital A (Malaysia, branding-to-logistics), and Allergy Therapeutics (UK, biopharmaceutical); it also notes Syngenta Group (Swiss, seeds/agrochemicals) plans a $10 billion listing in H2 2025. The pipeline includes 'first-time IPOs, concurrent dual listings and sequential dual listings', according to HKEX's Johnson Chui.

Foreign Firms Eye Hong Kong Listings as IPO Rebound Broadens

May 19, 2026

Major agrochemical and biotech firms, including Syngenta, are targeting Hong Kong IPOs amidst a broader market rebound. HKEX reports increased international interest across sectors like mining and pharmaceuticals beyond traditional China exposure.

reuters

2026-02-06

Syngenta Considers Hong Kong IPO

2026-05-19

Foreign Firms Eye Hong Kong Listings as IPO Rebound Broadens

2026-07-15

Syngenta's $5 Billion HK IPO Pushed Back Amid Agriculture Sector Uncertainty, Bloomberg Reports

Foreign Firms Eye Hong Kong Listings as IPO Rebound Broadens

FAQ